211 related articles for article (PubMed ID: 19907230)
1. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
Choy-Shan A; Berezovskaya S; Zinn A; Sedlis SP; Bini EJ
Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
[No Abstract] [Full Text] [Related]
2. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
3. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Rogers CJ; Romagosa R; Vincek V
J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
[No Abstract] [Full Text] [Related]
4. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M
Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303
[No Abstract] [Full Text] [Related]
5. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
Lin J; Lott JP; Amorosa VK; Kovarik CL
J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
[No Abstract] [Full Text] [Related]
6. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection.
Adişen E; Dizbay M; Hizel K; Ilter N
Indian J Dermatol Venereol Leprol; 2008; 74(1):60-2. PubMed ID: 18187830
[No Abstract] [Full Text] [Related]
7. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
8. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186
[No Abstract] [Full Text] [Related]
9. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
[No Abstract] [Full Text] [Related]
10. Retinal thrombosis secondary to the combination therapy of pegylated interferon and ribavirin for chronic hepatitis C virus infection. A rare complication.
Ortega-Ibarra FS; Remes-Troche JM
Rev Esp Enferm Dig; 2013; 105(5):291-2. PubMed ID: 23971660
[No Abstract] [Full Text] [Related]
11. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
Shafa S; Borum ML; Igiehon E
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):122-3. PubMed ID: 19959941
[No Abstract] [Full Text] [Related]
12. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
[No Abstract] [Full Text] [Related]
13. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
Oiso N; Sato M; Kawada A
J Dermatol; 2013 Sep; 40(9):772-3. PubMed ID: 23855823
[No Abstract] [Full Text] [Related]
14. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
Condat B; Asselah T; Zanditenas D; Estampes B; Cohen A; O'Toole D; Bonnet J; Ngo Y; Marcellin P; Blazquez M
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
[TBL] [Abstract][Full Text] [Related]
15. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.
Sprenger R; Sagmeister M; Offner F
Gut; 2005 Mar; 54(3):438-9; author reply 439. PubMed ID: 15710996
[No Abstract] [Full Text] [Related]
16. Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
Keeffe EB; Kowdley KV
J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S1-2. PubMed ID: 15597022
[No Abstract] [Full Text] [Related]
17. [Anterior uveitis in a patient treated with pegylated interferon and ribavirin].
Carneros Martín JA; Fuentes Coronel A; Alvarez Delgado A; González San Martín F
Med Clin (Barc); 2003 Mar; 120(9):359. PubMed ID: 12646118
[No Abstract] [Full Text] [Related]
18. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
Veldt BJ; Schalm SW; Janssen HL
J Clin Gastroenterol; 2007 Apr; 41(4):432. PubMed ID: 17413616
[No Abstract] [Full Text] [Related]
19. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Enjoji M; Dainichi T; Gondo H; Urabe K
Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
[TBL] [Abstract][Full Text] [Related]
20. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
